Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

FWBI


Top 10 Correlated ETFs

FWBI


Top 10 Correlated Stocks

FWBI


In the News

07:00 03 Oct 2022 FWBI

First Wave BioPharma's CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference

BOCA RATON, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President, and CEO of First Wave BioPharma, will give a presentation and take investor meetings at the Inaugural Roth Healthcare Opportunities Conference taking place October 6, 2022, in New York City.

07:00 03 Oct 2022 FWBI

First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022

BOCA RATON, Fla., Aug. 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, will present at the 2022 H.C. Wainwright 24th Annual Global Investment Conference. The conference is taking place September 12-14, 2022, at the Lotte New York Palace Hotel, New York City.

08:05 03 Oct 2022 FWBI

Why First Wave BioPharma Shares Are Tanking Today

First Wave BioPharma Inc (NASDAQ: FWBI) shares are plummeting after the company reported topline data from Phase 2 RESERVOIR trial of FW-COV, oral formulation of niclosamide, for COVID-19-related GI infections. FW-COV was very safe, with no serious adverse events reported by the more than 150.

09:25 03 Oct 2022 FWBI

Trading Penny Stocks? Top Stock Market News for March 31st, 2022

Here's what you need to know about trading penny stocks on March 31st The post Trading Penny Stocks? Top Stock Market News for March 31st, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

07:30 03 Oct 2022 FWBI

First Wave BioPharma to Participate in the 2022 BIO CEO & Investor Conference

BOCA RATON, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, will deliver a virtual presentation at the 2022 BIO CEO & Investor Conference. The event is taking place February 14-17, 2022, at the New York Marriott Marquis as a hybrid conference that allows virtual and in-person participation.

08:52 03 Oct 2022 FWBI

First Wave BioPharma Files Two Provisional US Patent Applications For Adrulipase

First Wave BioPharma Inc (NASDAQ: FWBI) has filed two new provisional patent applications on adrulipase with the U.S. Patent and Trademark Office (USPTO).  The first application is directed to new lipase dosage forms, treatment methods, and manufacturing.

07:00 03 Oct 2022 FWBI

First Wave BioPharma to Participate in Two Investor Conferences in January 2022

CEO James Sapirstein to Moderate Panel Discussion during Longwood Healthcare Leaders Conference and Host Virtual Presentation at H.C. Wainwright BioConnect 2022 CEO James Sapirstein to Moderate Panel Discussion during Longwood Healthcare Leaders Conference and Host Virtual Presentation at H.C. Wainwright BioConnect 2022

11:06 03 Oct 2022 FWBI

4 Penny Stocks To Buy For Under $5 Before 2022

You can buy these penny stocks for under $5 but are they worth the risk? The post 4 Penny Stocks To Buy For Under $5 Before 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

08:33 03 Oct 2022 FWBI

First Wave BioPharma Stock Jumps On Niclosamide's Favorable Safety Profile In COVID-19 Related GI Infections

The independent data monitoring committee (DMC) has recommended First Wave BioPharma Inc (NASDAQ: FWBI) to continue enrollment in Part 2 of the RESERVOIR Phase 2 trial evaluating FW-COV for COVID-19-related gastrointestinal (GI) infections.  FW-COV is a proprietary, oral tablet formulation of micronized niclosamide developed to remove SARS-CoV-2 from the GI tract.

08:25 03 Oct 2022 FWBI

First Wave BioPharma stock rockets after upbeat news on treatment for COVID-19-related GI infections

Shares of First Wave BioPharma Inc. FWBI, -2.58% rocketed 46.6% on very heavy volume in premarket trading Tuesday, after the biopharmaceutical company said an independent data monitoring committee (DMC) recommended continued enrollment in a Phase 2 trial of its treatment (FW-COV) for COVID-19-related gastrointestinal (GI) infections. Trading volume spiked to 12.0 million shares ahead of the open, enough to make the stock the most actively traded in the premarket, and compared with the full-day average of about 1.4 million shares.

Financial details

Company Rating
Neutral
Market Cap
2.05M
Income
58537.85B
Revenue
0
Book val./share
-19.52
Cash/share
1.59
Dividend
-
Dividend %
-
Employees
17
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-0.07
P/C
0.93
P/FCF
-0.03
Quick Ratio
0.07
Current Ratio
0.1
Debt / Equity
-0.02
LT Debt / Equity
-0.02
-
-
EPS (TTM)
-187.98M
EPS next Y
-
EPS next Q
-
EPS this Y
57081669.09%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-59.96%
-
-
-
-
SMA20
-60.06%
SMA50
-73.66%
SMA100
-89.24%
Inst Own
3.43%
Inst Trans
-2.81%
ROA
-1490546549%
ROE
612621985%
ROC
4.22%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
1.39M
Shs Float
1.38M
-
-
-
-
Target Price
270
52W Range
1.19-106.5
52W High
-98.6%
52W Low
+48%
RSI
30.21
Rel Volume
0.47
Avg Volume
866.54K
Volume
410.88K
Perf Week
5.71%
Perf Month
-67.76%
Perf Quarter
-93.76%
Perf Half Y
-94.81%
-
-
-
-
Beta
1.78825
-
-
Volatility
0.09%, 1.13%
Prev Close
2.07%
Price
1.48
Change
2.07%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
00000
Net income per share
-313.2-262.97-203.04-344.68-196.75M
Operating cash flow per share
-202.79-211.2-187.73-118.39-108.52
Free cash flow per share
-203.7-212.28-188.06-118.43-108.76
Cash per share
16.1921.652.3563.9527.72
Book value per share
46.8786.9361.77-27.86-26.29
Tangible book value per share
-48.0338.45-9.05-79.91-32.71
Share holders equity per share
46.8786.9361.77-27.86-26.29
Interest debt per share
36.466.9327.2768.2537.76K
Market cap
1.23M1.04M679.49K1.38M357.03K
Enterprise value
1.08M185.42K2.11M-4.05M-7.89M
P/E ratio
-0.11-0.08-0.04-0.040
Price to sales ratio
00000
POCF ratio
-0.17-0.1-0.05-0.12-0.01
PFCF ratio
-0.17-0.1-0.05-0.12-0.01
P/B Ratio
0.740.230.15-0.52-0.05
PTB ratio
0.740.230.15-0.52-0.05
EV to sales
00000
Enterprise value over EBITDA
-0.12-0.01-0.150.160
EV to operating cash flow
-0.15-0.02-0.150.360.24
EV to free cash flow
-0.15-0.02-0.150.360.24
Earnings yield
-9-12.95-22.34-23.61-163.96M
Free cash flow yield
-5.85-10.46-20.69-8.11-90.63
Debt to equity
000-0.010
Debt to assets
0.70.40.481.21.66
Net debt to EBITDA
0.020.07-0.10.210
Current ratio
0.791.60.80.510.77
Interest coverage
-11.68-131.88-33.98-4.53-0.01
Income quality
0.650.80.920.340
Dividend Yield
000012.62
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.610.330.590.380.16
Capex to operating cash flow
00.01000
Capex to revenue
00000
Capex to depreciation
-0.04-0.07-0.02-0.01-4.72
Stock based compensation to revenue
00000
Graham number
574.71717.19531.21464.82341.14K
ROIC
-3.41-3-3.1910.08115.7
Return on tangible assets
-5.24-2.72-4.21-4.09-5.93M
Graham Net
-68.239.68-28.52-95.89-38.19
Working capital
-526.51K1.8M-877.35K-7.68M-2.88M
Tangible asset value
-1.7M1.98M-676.53K-7.57M-9.73M
Net current asset value
-1.87M1.8M-877.35K-7.69M-10.19M
Invested capital
0.250.060.35-0.240
Average receivables
827.81K1.86M1.59M551.49K0
Average payables
1.13M1.88M1.89M1.56M0
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-6.68-3.03-3.2912.377.48M
Capex per share
-0.91-1.08-0.32-0.04-0.23

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
00000
Net income per share
-35.63-97.62-187.98M-18.58-7.44
Operating cash flow per share
-21.59-50.51-18.83-15.27-17.19
Free cash flow per share
-56.44-54.5214.09-15.27-17.19
Cash per share
31.0123.1526.4910.991.59
Book value per share
27.02-22.38-25.12-17.83-19.52
Tangible book value per share
9.33-36.6-31.26-21.43-21.94
Share holders equity per share
27.02-22.38-25.12-17.83-19.52
Interest debt per share
2.11.2636.08K1.440.43
Market cap
2.14M875.07K449.99K549.25K145.38K
Enterprise value
-5.4M-5.95M-7.8M-4.41M-698.73K
P/E ratio
-0.06-0.010-0.01-0.01
Price to sales ratio
00000
POCF ratio
-0.38-0.06-0.08-0.07-0.01
PFCF ratio
-0.15-0.050.1-0.07-0.01
P/B Ratio
0.3-0.13-0.06-0.06-0.01
PTB ratio
0.3-0.13-0.06-0.06-0.01
EV to sales
00000
Enterprise value over EBITDA
0.590.200.460.13
EV to operating cash flow
0.960.381.330.560.06
EV to free cash flow
0.370.35-1.780.560.06
Earnings yield
-4.35-34.74-130.09M-17.53-37.2
Free cash flow yield
-6.88-19.49.75-14.41-85.96
Debt to equity
0.04-0.040-0.03-0.02
Debt to assets
0.491.561.662.054.61
Net debt to EBITDA
0.820.2300.520.16
Current ratio
1.330.390.770.460.1
Interest coverage
-3.14K-40.97K0-1.67K-1.68K
Income quality
0.610.5200.822.31
Dividend Yield
0010.0200.33
Payout ratio
0000-0.01
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.330.360.160.210.45
Capex to operating cash flow
00.08-0.200
Capex to revenue
00000
Capex to depreciation
0-9.02-3.0200
Stock based compensation to revenue
00000
Graham number
147.19221.72325.93K86.3457.16
ROIC
-1.274.5521.881.740.4
Return on tangible assets
-1.01-3.8-5.93M-1.38-2.49
Graham Net
5.12-39.12-36.49-23.83-23.26
Working capital
2.16M-11.6M-2.88M-7.67M-15.49M
Tangible asset value
2.43M-11.4M-9.73M-11.1M-15.95M
Net current asset value
1.88M-11.89M-10.19M-11.52M-16.33M
Invested capital
0.08-0.060-0.08-0.02
Average receivables
00028.06K49.24K
Average payables
3.95M10.95M03.45M3.71M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-1.324.367.48M1.040.38
Capex per share
0-4.013.7800

Frequently Asked Questions

What is First Wave BioPharma, Inc. stock symbol ?

First Wave BioPharma, Inc. is a US stock , located in Boca raton of Fl and trading under the symbol FWBI

Is First Wave BioPharma, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $270. The lowest prediction is $270 and the highest is $270

What is FWBI stock prediction ?